Eucalyptus and Pilot: The Australian Digital Health Startup That Sold for $1.6 Billion
In February 2026, The Australian reported that Eucalyptus: the Sydney-based digital health startup behind Pilot (men’s health) and Juniper (women’s health): was sold to a US healthcare company for AU$1.6 billion. It was one of Australia’s largest healthcare exits and a validation of the digital-first, AI-assisted healthcare model the company pioneered.
What Eucalyptus Built
Eucalyptus took a “digital clinic” model: combining telehealth consultations with AI-assisted assessments and direct-to-consumer medication delivery: and applied it to specific health conditions where the traditional healthcare system was underserving patients. Its brands:
- Pilot: Men’s health: hair loss, erectile dysfunction, mental health, weight management. Built around making it easy for men to get treatment they’d previously avoided due to embarrassment or access barriers
- Juniper: Women’s health: weight management (including GLP-1 medications), menopause, general wellness
- Kin: Fertility and preconception care
- Software: General wellness and skincare
The AI and Technology Model
Eucalyptus’s clinical model uses AI at multiple points: intake assessments that gather symptom and medical history data efficiently, triage algorithms that identify which patients need urgent clinical attention, personalised treatment plans generated from clinical guidelines and patient data, and ongoing monitoring that adjusts treatment based on patient-reported outcomes.
The result is healthcare that’s faster, more accessible, and: for appropriate conditions: more consistently delivered than traditional GP-and-pharmacy pathways. Pilot’s hair loss and ED treatments, for example, can be prescribed, dispensed, and delivered without a patient leaving their home, in a fraction of the time of a traditional GP visit.
The Controversy
Eucalyptus has not been without controversy. A December 2025 report scrutinised marketing of weight-loss treatments: specifically around “pesky Aussie laws” language that critics said reflected a cavalier attitude toward Australian healthcare regulation. The company has faced questions about whether its AI-assisted model adequately replaces in-person clinical assessment for certain conditions.
These tensions: between access and safety, between speed and thoroughness: are inherent in AI-assisted healthcare. Eucalyptus pushed the boundaries of what’s possible; the regulatory response will shape how the industry develops.
Why the $1.6B Exit Matters
The sale validates a model: AI-assisted digital health, built in Australia for Australian conditions, can reach a scale and quality that global healthcare companies want to acquire. It also signals that Australian digital health exits are possible at significant scale: important context for the next generation of health tech founders.
📖 AI for allied health → | Coviu telehealth profile →
📖 ← Australian AI Companies: Full Roundup
Sources and Further Reading
- Eucalyptus. Official Website
- Pilot. Official Website
- The Australian. Eucalyptus acquisition coverage
- AFR. Digital health in Australia
📋 Browse all Australian AI company profiles: Australian AI Companies: The Complete Guide by Industry (2026) →
This profile is part of SmallBizAI.au’s guide to Australian AI companies by industry and our Australian AI Companies directory.
📊 Compare AI tools side by side | 💼 Free resources & AI prompt packs
📖 More deep dives: News Deep Dives
